QUALITY OF LIFE IN PATIENTS WITH EPILEPSY – SINGLE CENTRE EXPERIENCE

Andrea Bujan Kovač, Željka Petelin Gadže, Katarina Ivana Tudor, Sibila Nanković, Vlatko Šulentić, Zdravka Poljaković, Goran Mrak, Monika Mudrovčić, Ira Brezak, Dragana Mijatović, Filip Đerke, Andrej Desnica, Jakob Némir, Ivana Čajić, Petra Nimac Kozina, Biljana Đapić Ivančić, Borislav Radić and Sanja Hajnšek

1Department of Neurology, Zagreb University Hospital Centre, School of Medicine, University of Zagreb, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy, Affiliated Partner of the ERN EpiCARE, Zagreb, Croatia;
2Department of Neurosurgery, Zagreb University Hospital Centre, School of Medicine, University of Zagreb, Affiliated Partner of EUROCAN, Zagreb, Croatia;
3Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia;
4Klinički studio, Private Psychology Practice, Zagreb, Croatia;
5Istrian Health Centre, Umag Section, Umag, Croatia;
6Department of Neurology, Dubrava University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia;
7Sveti Ivan Psychiatric Hospital, Zagreb, Croatia

SUMMARY – A prospective study was carried out at the Zagreb University Hospital Centre to evaluate the relationship between epilepsy, antiepileptic drugs (AEDs) and quality of life (QoL) in patients with epilepsy (PE), and its association with depressive symptoms and sexual dysfunction (SD). QoL was assessed by use of the Quality of Life in Epilepsy-31 Inventory (QOLIE-31), SD by the Arizona Sexual Experiences Scale (ASEX), and depressive symptoms by the Hamilton Rating Scale for Depression (HAM-D17). The study included 108 PE (women 63% and men 37% men), mean age 39.54±15.91 years. Focal type epilepsy was diagnosed in 14.8%, generalized type in 35.2%, and both types were present in 40.7% of study patients. Drug-resistant epilepsy (DRE) was present in 44/108 and vagus nerve stimulation (VNS) was implanted in 27/44 patients. The mean response on QOLIE-31 was 62.88±17.21 with no significant differences according to gender, type of epilepsy, and age. A statistically significantly lower QoL was found in the ‘Overall QoL’ domain (35-55 vs <35 age group). Patients taking both types of AEDs had a significantly lower QoL compared to those on newer types of AEDs. Higher QoL was associated with less pronounced depressive symptoms (p=0.000). Significant correlations were found between lower QoL and SD (p=0.001). In 27 patients with DRE having undergone VNS, a favorable effect of VNS implantation on the QoL and mood was observed as compared with 18 patients without VNS (p=0.041).

Key words: Epilepsy; Quality of life; Antiepileptic drugs; QOLIE-31; Drug-resistant epilepsy; Vagus nerve stimulation

Introduction

The World Health Organization (WHO) defines quality of life (QoL) as “an individual’s perception of their position in life in the context of the culture and
value systems in which they live and concerning their goals, expectations, standards, and concerns. Patients with epilepsy as a chronic disease are at risk of impaired health-related quality of life (HRQoL), which is not solely confined to the fear of recurrent seizures and physical injury associated with seizures but also to the risks of treatment-related side effects, lifestyle restrictions, physical difficulties, and perceived stigmatization that frequently results in social exclusion and isolation, as well as difficulties in accessing educational services and obtaining employment due to the presence of cognitive or psychiatric problems.

Psychiatric comorbidities and disorders such as depression, anxiety, psychosis, inattention, obsession, personality traits, aggression, and suicide are frequent in patients with epilepsy and have a significant impact on medical management and QoL. They are related not only to psychosocial factors but also to structural (epilepsy process and epileptogenesis) mechanisms, as well as an adverse effect of antiepileptic drugs (AEDs). Epilepsy and depression seem to have a bidirectional association, in probably shared pathophysiological mechanism caused by impairment of cellular metabolism associated with the process of epileptogenesis, neuronal plasticity and changes in hypothalamic–pituitary axis (HPA), neurotransmitters and pathways due to epilepsy. Furthermore, increasing GABA-mediated inhibitory activity, glutamate blockage activity, alteration of serotonergic, adrenergic and noradrenergic neurotransmitters and pathways might contribute to behavioral changes associated with AEDs. The risk of depression and other psychiatric disorders appears to be particularly high in epilepsy patients with intellectual disability. Furthermore, anxiety about seizures, added to the actual occurrence of seizures, has also been shown to be one of the most important factors affecting QoL in patients with epilepsy.

The incidence of sexual dysfunction (SD) in male patients with epilepsy is 5 times higher compared to healthy population, and the incidence of sexual hyperactivity is about 2.9%. Sexual disturbances are not only influenced by AEDs but also by epilepsy itself, especially in temporal lobe epilepsy, where abnormal brain epileptiform discharges may directly interfere with the function of the hypothalamic–pituitary–gonadal axis, which may cause abnormalities in the secretion of sex hormones and lead to reproductive endocrine disorders. Studies have shown that AEDs, especially older ones such as carbamazepine (CBZ), phenytoin (PHT) and phenobarbital (PB) that are enzyme inducer classes, and valproate (VPA) as liver enzyme inhibitor can cause endocrine disorders in male patients with epilepsy and lead to a decrease in fertility. Newer AEDs, oxcarbazepine (OXC), levetiracetam (LEV), or lamotrigine (LTG) might affect sexual function less than older AEDs, and some studies have shown that these AEDs have no significant effect on sexual function and sex hormones.

Current treatment options for patients with drug-resistant epilepsy (DRE) include pharmacotherapy with AEDs, surgical removal of the seizure focus, and alternative approaches such as neurostimulation, ketogenic diet, and lifestyle changes. Vagus nerve stimulation (VNS) is a viable, minimally invasive neurosurgical treatment option for DRE. As the published studies on VNS in epilepsy have reported improvement in QoL after VNS implantation, we included patients with implanted VNS in our study.

As there are different variables influencing QoL, in addition to different psychiatric comorbidities and SD that further decrease QoL, QoL has recently been increasingly measured in epilepsy patients in clinical and research practice using a variety of surveys, scales, and questionnaires that study particular cohorts of patients with epilepsy, impact of seizure treatments, epilepsy surgery, cultural differences and patient education, as well as other parameters influencing their QoL.

Patients and Methods

Participants

A prospective cross-sectional study was conducted at the Department of Neurology, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy, Zagreb University Hospital Centre, Zagreb, Croatia (a tertiary teaching hospital) to assess the impact of AEDs and VNS treatment on the QoL of our patients with epilepsy during the period of 18 months. The study was approved by the Ethics Committee of the Zagreb University Hospital Centre and all participants gave their informed consent to participate in the study.

The study included 108 patients with epilepsy. Demographic data were recorded, as well as data from patient history, e.g., gender, age, clinical phenotype of
seizures (focal, generalized, or combined focal and generalized epilepsy), and co-administered AEDs (new: lacosamide – LCS, LTG, LEV, OXC; pregabalin – PGB; topiramate – TPM; zonisamide – ZNS; and old: acetazolamide – ACT, CBZ; clobazam – CLB; clonazepam – CLN; ethosuximide – ESC; methylphenobarbital – MPB; sulthiame – SUL, VPA). The group of patients with DRE (n=44) included those with implanted VNS (n=27).

Questionnaires

Three questionnaires evaluating QoL, depressive symptoms and SD were administered to consecutive patients on their follow-up visits to the Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy, Zagreb, Croatia.

Quality of life was assessed using the Quality of Life in Epilepsy Inventory-31 items (QOLIE-31) as the most widely used questionnaire previously validated for Croatian language and population. This scale contains seven multi-item scales that enquire the following domains: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life. The weighted average of these domains together makes an overall score and the QOLIE-31 also includes a single item that assesses overall health.13,14

Depressive symptoms were evaluated using the Hamilton Rating Scale for Depression (HAM-D17), the most widely used clinician-administered depression assessment scale, while SD was evaluated using the Arizona Sexual Experience Scale (ASEX), a questionnaire commonly used in clinical trials to assess sexual functioning.15 The latter two were not in the focus of this study and their purpose here was to give an insight into the relationship of QoL with depressive symptoms and SD.

Statistical analysis

All statistical data analyses were performed using SPSS version 20.0.17 The following statistical tests were performed: t-test for means correlations, one-way ANOVA, post hoc Scheffe test for multiple comparisons, Bonferroni correction test for multiple univariate analyses, Tukey test and Pearson correlation coefficient for scale data associations. The Mann-Whitney test was performed for nonparametric two-sample analysis.

Results

The study included 108 patients with epilepsy, mean age 39.54±15.91 (range 18–80) years. There were 68 (63%) women and 30 (37%) men, mean age 38.07±16.14 (range 18–77) and 42.10±15.37 (18–80) years, respectively. Sixteen (14.8%) patients had focal, 38 (35.2%) generalized and 44 (40.7%) both types of epilepsy. The majority of patients (24%) were in the 26–35 age group (Fig. 1). The majority of patients (n=71, 65.74%) were treated with two or more AEDs, and 25% (n=27) were treated with one AED. The majority (42%) of patients were treated with new AEDs, 39% with both types of AEDs, and 19% with old AEDs (Fig. 2).
The mean response on the QOLIE-31 was 62.88±17.21 (range 15.48-89.06); the mean overall response was 63.31±16.51 in women and 62.18±18.51 in men (Table 1). There were no significant gender differences in the QOLIE-31 (Table 2). Except for the ‘Overall QoL’ domain, found to be statistically significantly lower in the 35–55 age group in comparison to the <35 age group, no other statistically significant differences were recorded according to age and QOLIE-31 responses. We found no statistically significant differences according to the type of epilepsy and QOLIE-31 results either.

There was a statistically significant difference in QOLIE-31 responses between patients treated with new AEDs and those treated with both types of AEDs (p=0.002). The latter had a significantly lower QoL. Also, QoL was found to be significantly lower in both men and women treated with both types of AEDs in comparison to those treated with new AEDs. Women treated with old AEDs had better QoL than those treated with new AEDs and with both types of AEDs. Men treated with new AEDs were found to have better QoL when compared to those treated with old AEDs and with both types of AEDs (Fig. 3).

When analyzing different domains on QOLIE-31 and interaction with AEDs, statistically significant differences (p<0.05) were found on the following domains: ‘Seizure worry’ was more pronounced in those treated with new AEDs as compared to those treated with both types of AEDs; ‘Overall quality of life’ revealed better QoL in those treated with new AEDs as compared to those treated with both types of AEDs; ‘Emotional wellbeing’ yielded lower emotional wellbeing scores in those treated with old AEDs as compared to those treated with new AEDs; ‘Cognitive functioning’ and ‘Social functioning’ showed higher, i.e. better scores in patients treated with old and new AEDs as compared to patients taking both types of AEDs. No significant differences were found in the ‘Energy/fatigue’ and ‘Medication effects’ domains according to the type of AEDs.

We found a strong negative correlation between higher QoL and HAM-D17 (p=0.000). Significant correlations were found between lower QoL and SD (p=0.001). Higher QoL was found to be associated with less pronounced symptoms of SD (r=-0.34) and depression (r=-0.71), whereas more pronounced SD symptoms were associated with more pronounced depressive symptoms (r=0.35) (Table 3).

Table 1. Mean results on QOLIE-31 according to gender (group statistics)

| Gender   | N  | Mean   | SD    | SE   |
|----------|----|--------|-------|------|
| QOLIE-31 |    |        |       |      |
| Men      | 35 | 62.189 | 18.514| 3.129|
| Women    | 57 | 63.316 | 16.516| 2.188|

QOLIE-31 = Quality of Life in Epilepsy-31 Inventory; SD = standard deviation; SE = standard error of mean

Table 2. QOLIE-31 mean response according to gender (independent samples test)

| Levene’s test for equality of variances | Equal variances assumed | Equal variances not assumed |
|----------------------------------------|-------------------------|-----------------------------|
| F                                      | 0.49300                 | 0.48400                     |
| Sig.                                   |                         |                             |
| t-test for equality of means           |                         |                             |
| t                                      | -0.30300                | -0.29500                    |
| df                                     | 90                      | 65.80500                    |
| Sig. (2-tailed)                        | 0.76300                 | 0.76900                     |
| Mean difference                        | -1.12597                | -1.12597                    |
| Std. error difference                  | 3.71478                 | 3.81841                     |
| 95% confidence interval of difference  |                         |                             |
| Lower                                  | -8.50603                | -8.75009                    |
| Upper                                  | 6.25409                 | 6.49814                     |

QOLIE-31 = Quality of Life in Epilepsy-31 Inventory
Additionally, our study group included 44 patients with DRE, including 27 patients treated with VNS and six patients underwent epilepsy surgery due to mesial temporal sclerosis (selective amygdalohippocampectomy, n=4), focal cortical dysplasia (n=1) and cavernoma (n=1). These patients were divided into two groups: 27 patients with implanted VNS as case group (14 M, 13 F; mean age 34.7±28.3) and 18 control patients with DRE without implanted VNS (10 M, 8 F; mean age 45.2±30.8). The mean response on the QOLIE-31 was 69.47±16.23 in patients treated with VNS versus 52.9±20.62 in the control group. Mann-Whitney test yielded a significant difference in the QOLIE-31 score between the case group and control group (p=0.041). In the case group, younger patients had a lower QOLIE-31 score, but the difference was not statistically significant.

**Discussion**

In our study, the mean response on QOLIE-31 was 62.88±17.21, which is slightly higher than the global mean QOLIE-31 score of 59.818. We found no statistically significant QoL difference according to the type of epilepsy seizures, and in the literature, there is a controversy regarding the type of seizures that mostly affects QoL. Some studies indicate that people with generalized epilepsy have lower QoL, whereas others report on focal epilepsy association with lower QoL, but most studies could not find strong correlation between seizure types and QoL but emphasize the impact of seizure frequency and duration of epilepsy on QoL19-21.

Our results showed gender differences, meaning that our female patients reported better QoL than men. This is different from literature data, where some studies support the hypothesis of no gender differences in QoL, and others do not; however, in those that do it women's QoL is always rated lower than men's QoL. Some of the factors resulting in lower QoL are partially explained with lower medical care and poorer social support for women in low-income

---

**Table 3. Correlations among the QOLIE-31, HAM- D17 and ASEX questionnaires**

|                  | QOLIE-31_total | ASEX_total | HAM- D17_total |
|------------------|----------------|------------|---------------|
| QOLIE-31_total   | Pearson correlation | Sig. (2-tailed) | 1  | -0.339** | -0.705** |
|                  | n             |            | 92 | 0.001  | 0.000  |
|                  |               |            |    | 85     | 72     |
| ASEX_total       | Pearson correlation | Sig. (2-tailed) | -0.339** | 1  | 0.347** |
|                  | n             |            | 0.001 | 94 | 0.003  |
|                  |               |            | 85   |    | 72     |
| HAM- D17_total   | Pearson correlation | Sig. (2-tailed) | -0.705** | 0.347** | 1  |
|                  | n             |            | 0.000 | 72 | 79     |
|                  |               |            | 72   |    |        |

QOLIE-31 = Quality of Life in Epilepsy-31 Inventory; HAM- D17 = Hamilton Rating Scale for Depression; ASEX = Arizona Sexual Experience Scale; **correlation significant at the 0.01 level (2-tailed)
countries, and with different psychosocial factors in developed countries.\(^{22-24}\)

When comparing different age groups, we did not find statistically significant differences in QOLIE-31 on the overall score, but it was found to be statistically significantly lower in the ‘overall QoL’ subscale in the 35–55 age group as compared to the <35 age group. When looking into the literature on patients with epilepsy, their age and gender did not show any significant impact on QoL.\(^{21}\) In our study, we did not compare patients with epilepsy to healthy controls, but in previous studies, it has been reported that patients with epilepsy have lower QoL compared to healthy controls.\(^{25-27}\)

Patients taking modern AEDs have better QoL compared to those taking both old and modern AEDs (p=0.002), which applies to both men and women. It is generally assumed that modern AEDs have the same efficacy as older ones and better tolerability, but they also have side effects, especially cognitive and psychiatric. As this was a tertiary level center investigation, many of the patients enrolled in the study had DRE with seizures difficult to treat and leading to AED polytherapy. Furthermore, although monotherapy is preferred, there is evidence for the efficacy of combination AEDs with different or multiple mechanisms of action for better seizure control. According to literature data, polytherapy is associated with a higher level of AEDs, associated side effects, and lower QoL.\(^{10}\)

Other studies such as SANAD have demonstrated that newly diagnosed patients with epilepsy are cognitively compromised before starting AED treatment and that the domains most affected were memory and psychomotor speed, which leads to a conclusion that seizures may themselves result in cognitive impairment.\(^{28}\) On the other hand, cognitive impairment increases the likelihood of physical injury in patients with epilepsy, thus all resulting in lower QoL.\(^{3,4}\) In our study patients taking only modern or old AEDs reported better cognitive functioning than patients taking both old and modern AEDs.

Our study patients taking modern AEDs reported better emotional well-being compared to patients taking old AEDs. Thus, according to literature data, psychiatric and behavioral side effects occur more frequently in patients taking new AEDs (LEV, ZNS), whereas lower rates were seen in patients taking old AEDs, i.e. CBZ, CLB, gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OXC), PHT and VPA. Higher rates of side effects with new AEDs caused higher rates of intolerability and led to AED discontinuation.\(^{29}\) The relationship between psychiatric disorders and epilepsy has relevant therapeutic implications, which should be directed towards a comprehensive biopsychosocial approach focused on the persons as a whole rather than simply on the disease process.\(^{6}\) In our study, we found a strong negative correlation between higher QoL and HAM-D17 (p=0.000), meaning that patients with pronounced depressive symptoms had lower QoL.

Patients taking modern AEDs are more worried about seizures than patients taking both modern and old AEDs, both women and men. This is probably to some extent due to the belief of our patients that old AEDs are more potent in reducing seizure frequency, and is consistent with the fact that seizure frequency and seizure types are two of the most important factors influencing QoL in patients with epilepsy. Fear of and worrying about having a seizure are common in patients with epilepsy, resulting in lowest scores on the ‘Seizure worry’ subscale compared to other subscales, both in men and women.\(^{12,19,30}\)

Social functioning was better in patients taking older or modern AEDs compared to patients taking both old and modern AEDs. Social functioning is to some extent influenced by the stigma associated with epilepsy as a chronic illness, resulting in discrimination in everyday activities, such as attending school, driving, working, and obtaining insurance.\(^{12,11,32}\) Deficiencies in social well-being may arise due to psychological factors resulting in impairment of the development of skills needed for social interaction such as parental overprotectiveness in childhood, stigmatization, reduced life experience opportunities, and fear of seizures. Furthermore, psychiatric symptoms such as depression and anxiety, or neurocognitive impairments in attention, memory, language, and processing speed, which are all common in patients with epilepsy, can contribute to social difficulties.\(^{12}\) Also, a higher education level of patients with epilepsy seems to be associated with better QoL, thus promoting the idea of continuing education and better social functioning in patients with epilepsy.\(^{23}\) Other data suggest a strong correlation between seizure frequency and polypharmacy, and their association with poorer QoL.\(^{27,34-36}\)
Modern treatment options for patients with DRE include pharmacotherapy with AEDs, surgical removal of the seizure focus, and alternative approaches such as neurostimulation, ketogenic diet, and lifestyle changes. VNS was approved in 1997 as adjunctive therapy for patients with DRE. Since then, VNS therapy has been provided to around 100,000 patients worldwide, and its beneficial effects in reducing seizure frequency have been reported in multiple long-term open-label studies. Furthermore, studies showed other potential benefits that reach beyond seizure reduction, decrease in the severity and duration of ictal or postictal phases but also benefits from improvement in mood, vigilance, communication and cognition, and the possibility of reducing AEDs and associated adverse effects. Thus, this leads to a conclusion that VNS-related improvement in HRQoL might reflect the sum of all these benefits or be mediated by these multiple factors.

This was also shown in our study, where patients with DRE reported higher QOLIE-31 scores as compared to DRE patients treated solely with AEDs.

**Conclusion**

Epilepsy is highly comorbid with other cognitive, physical and psychiatric disorders, which often additionally limit patient functional abilities in everyday functioning and it is therefore important to focus not only on the efficacy of AEDs or neurosurgery but to look at the patient in a more holistic manner, including comorbidities, side effects, and their overall QoL. The results of this study evaluating QoL in epilepsy patients demonstrated that patients taking both types of AEDs had significantly lower QoL in comparison to those on new AEDs. Higher QoL is associated with less pronounced depressive symptoms and SD. Also, our results in DRE patients showed that patients having undergone VNS reported better QoL compared to patients without VNS, and according to literature data, this effect may be the result not only of seizure reduction but multifactorial (i.e. mood improvement, vigilance, cognition).

The major limitation of this study was the lack of comparison with healthy population of Croatia. Furthermore, our results mostly reflect the QoL of patients with pharmacoresistant epilepsy, as this is a Referral Centre for Epilepsy for our country, where most difficult cases have been treated. Also, this was a single-center study with a small sample size. In the future, studies that will enroll more patients in comparison to healthy controls, performed with appropriate multivariate statistical methods that prospectively investigate the factors influencing QoL in patients with epilepsy are needed.

**References**

1. WHO Department of Mental Health. WHO Definition Quality of Life – Annotated Bibliography WHO/MNH/MHP/98.4.Rev.2 1999.
2. Pincus J. The Wellbeing of the Australian People: Comments on the Treasury’s Framework, 2014.
3. Kerr MP. The impact of epilepsy on patients’ lives. Acta Neurol Scand. 2012;126:1–9. doi: 10.1111/an.12014
4. Taylor J, Kolamunnage-Dona R, Marson AG, Smith PEM, Aldenkamp AP, Baker GA. Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia. 2010;51:48–56. doi: 10.1111/j.1528-1167.2009.02195.x
5. Hamed SA. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications. Expert Opin Drug Saf. 2011;10:913–34. doi:10.1517/14740338.2011.588597
6. Mula M. Developments in depression in epilepsy: screening, diagnosis, and treatment. Expert Rev Neurother. 2019;19:269–76. doi: 10.1080/14737175.2019.1585244
7. Hamed SA. Neuroendocrine hormonal conditions in epilepsy: relationship to reproductive and sexual functions. Neurologist. 2008;14:157–69. doi: 10.1097/NRL.0b013e3181618ada
8. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59:1344–50. doi: 10.1111/epi.14450
9. Bromfield EB, Herzog AG, Dworetzky BA, Schomer DL, Drislane FW, Pennell PB, et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology. 2006;65:1016–20. doi: 10.1212/01.wnl.0000178988.78039.40
10. Petelin Gadze Z, Poljakovic Z, Nankovic S, Sulentic V. Epilepsija – dijagnostički i terapijski pristup. Zagreb: Medicinska naklada, 2019. (in Croatian)
11. Ryvlin P, Gilliam FG, Nguyen DK, Colicchio G, Iudice A, Tinuper P, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLoE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia. 2014;55:893–900. doi: 10.1111/epi.12611
12. Schachter SC. Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev Neurother. 2006;6:111–8. doi: 10.1586/14737175.6.1.111
13. Devinsky O, Vickrey BG, JAC, KP, Hermann B, Meador K, et al. Development of the quality of life in epilepsy inventory. Epilepsia 1995;36:1089-104. doi: 10.1111/j.1528-1157.1995.tb00467.x

14. Lusic I, Dzamonja G, Tútic M, Bilic I, Sodic I, Lusic L, et al. Psychometric validation of the Croatian version of the Quality of Life in Epilepsy Inventory (QOLIE-31). Coll Antropol. 2011;35:1177-84.

15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;56-62. doi: 10.1136/jnnp.23.1.56

16. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25-38. doi: 10.1080/00926230027863

17. SPSS IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. n.d.

18. Saadi A, Patenaude B, Mateen FJ. Quality of Life in Epilepsy-31 Inventory (QOLIE-31) scores: a global comparison. Epilepsy Behav. 2016;65:13-7. doi: 10.1016/j.yebeh.2016.09.032

19. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38:353-62. doi: 10.1111/j.1528-1157.1997.tb01128.x.

20. Guekht AB, Mitrokhina TV, Lebedeva AV, Dzugaeva FK, Milchakova LE, Lokshina OB, et al. Factors influencing on quality of life in people with epilepsy. Seizure. 2007;16:128-33. doi: 10.1016/j.seizure.2006.10.011

21. Ashjazadeh N, Yadollahikhales G, Ayoobzadehshirazi A, Sadraei N, Hadi N. Comparison of the health-related quality of life between epileptic patients with partial and generalized seizure. Iran J Neurol. 2014;13:94-100.

22. Thusta E, Zaranova J, Simko J, Hozdikova H, Salek S, Vlcek J. Clinical and demographic characteristics predicting QOL in patients with epilepsy in the Czech Republic: how this can influence practice. Seizure. 2009;18:85-9. doi: 10.1016/j.seizure.2008.06.006

23. Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia. 2011;52:2168-80. doi: 10.1111/ j.1528-1167.2011.03213.x

24. Bala A, Szanto M, Gleinert A, Rysz A, Marchel A. Differences in quality of life of women and men with drug-resistant epilepsy in Poland. Epilepsy Behav. 2016;60:94-8. doi: 10.1016/j.yebeh.2016.04.041c

25. Kinyanjui DW, Khatuku DM, Mburu JM. Quality of life among patients living with epilepsy attending the Neurology Clinic at Kenyatta National Hospital, Nairobi, Kenya: a comparative study. Health Qual Life Outcomes. 2013;11:1-9.

26. Elger CE, Johnston SA, Hoppe C. Diagnosing and treating depression in epilepsy. Seizure. 2017;44:184-93. doi: 10.1016/j.seizure.2016.10.018

27. Siarava E, Hyphants T, Katsanos AH, Pelidou SH, Kyritsis AP. Markoula S. Depression and quality of life in patients with epilepsy in northwest Greece. Seizure. 2019;66:93-8. doi: 10.1016/j.seizure.2019.02.012

28. Jacoby A, Sudell M, Budur Smith C, Crossley J, Marson AG, Baker GA, on behalf of the SANAD Study Group. Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial. Epilepsia. 2015;56:460-72. doi.org/ 10.1111/epi.12913

29. Chen D, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24-31. doi: 10.1016/j.yebeh.2017.08.039

30. Ranjana, Dwajani S, Kulkarni C, Sarma GRK. The sociodemographic, clinical and pharmacotherapy characteristics influencing quality of life in people with epilepsy: a cross-sectional study. J Neurosci Rural Pract. 2014;5:7. doi: 10.4103/0976-4519.145193

31. Jacoby A. Behavior stigma, epilepsy, and quality of life. Heal (San Fr). 2002;3:10-20. doi: 10.1016/s1525-5050(02)00545-0

32. Yogarajah M, Mula M. Social cognition, psychiatric comorbidities, and quality of life in adults with epilepsy. Epilepsy Behav. 2019;3-5. doi: 10.1016/j.yebeh.2019.05.017

33. Ridgall L, Wojewodka G, Robinson E, Landau S, Noble A, Taylor S, et al. Characteristics associated with quality of life among people with drug-resistant epilepsy. J Neurol. 2017;264:1174-94. doi: 10.1007/s00415-017-8512-1

34. Johnson EK, Jones JE, Seidenberg M, Herrmann BP. The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy. Epilepsia. 2004;45:544-50.

35. Camara-Lamarroy CR, Hoyo M, Ibarra-Yruegas BE, Díaz-Torres MA, De León R. Affective symptoms with seizure frequency: results from a multicenter follow-up study. Seizure. 2017;53:103-9. doi: 10.1016/j.yebeh.2017.11.008
KVALITETA ŽIVOTA BOLESNIKA S EPILEPSIJOM – NAŠA ISKUSTVA

A. Bujan Kovač, Ž. Petelin Gadže, K. Ivana Tudor, S. Nanković, V. Šulentić, Z. Poljaković, G. Mrak, M. Mudrović, I. Brezak, D. Mijatović, F. Derke, A. Desnica, J. Nemir, I. Čajić, B. Đapči Ivaničić, B. Radić i S. Hajnšek

Provedeno je prospektivno istraživanje u KBC-u Zagreb s ciljem procjene povezanosti epilepsije, antiepileptičkih lijekova (antiepileptic drug, AED) i kvalitete života (quality of life, QoL) u bolesnika s epilepsijom, kao i učestalosti depresije i seksualne disfoncije (SD). QOLIE-31 (Quality of Life in Epilepsy-31 Inventory) je primijenjen za procjenu QoL-a, ASEX (Arizona Sexual Experiences Scale) za SD i HAM-D17 (Hamilton Rating Scale) za depresiju. Uključeno je 108 bolesnika s epilepsijom (63% žena, 37% muškaraca; srednja dob 39,54±15,91 godina). Žarišnu epilepsiju imalo je 14,8% i generalizirano 35,2% bolesnika, dok je obje vrste epilepsije imalo 40,7% bolesnika. Farmakorezistentnu epilepsiju (drug-resistant epilepsy, DRE) imalo je 44/108 bolesnika, a kod njih 27/44 ugrađen je stimulator vagusnog živca (vagus nerve stimulation, VNS). Srednji odgovor na QOLIE-31 bio je 62,88±7,21 bez značajnih razlika u odnosu na spol, vrstu epilepsije i dob. Statistički značajno niži QoL naden je u domeni ‘Sveukupni QoL’ (dobra skupina 35–55 godina u odnosu na dobnu skupinu <35). Bolesnici koji su uzimali obje AED imali su značajno niži QoL u usporedbi s onima na novijim AED. Viši QoL bio je povezan s manje izraženim simptomima depresije (p=0,000). Pronađene su značajne korelacije između nižeg QoL-a i SD (p=0,001). U bolesnika s DRE utvrđen je pozitivan utjecaj ugradnje VNS-a na QoL i raspoloženje (27 bolesnika s VNS-om u usporedbi s 18 bolesnika bez VNS-a, p=0,041).

Ključne riječi: Epilepsija; Kvaliteta života; Antiepileptički lijekovi; QOLIE-31; Farmakorezistentna epilepsija; Stimulator vagusnog živca